Description

Global Gene Editing Market Outline

 

Gene editing or Genome editing is the type of genetic editing where DNA is inserted, replaced or deleted in the genome of an organism in order to treat a specific disease by using a molecular scissors or engineered nuclease. These nucleases create site-specific double-stranded breaks in desired locations in genome. The induced double-stranded breaks are repaired through nonhomologous end joining or homologous recombination resulting in targeted mutations (edits).

 

Rise in the prevalence rate of cancer & other genetic disorders, increasing preference in the  personalized medicine, companies investments towards R&D, and growth of biotechnology and pharmaceutical industries, increase in private and public sector funding, rapid advancements in sequencing and gene editing technologies, applications in various drug discovery processes are some of the factors propelling the growth of the gene editing market. However, global gene editing market is hindered by stringent government regulations to approve gene mutation projects, ethical issues, unavailability of gene editing based therapeutics in the market and lack of awareness among people regarding the safety of genetic interventions.

 

SCOPE OF GLOBAL GENE EDITING MARKET

 

Gene Editing Market

Gene Editing Market

 

On the basis of technology, Global Market is segmented as:

  • Zinc Finger Nuclease (ZFN)
  • Clustered regularly interspaced short palindromic repeats (CRISPR)
  • Transcription activator-like effector nuclease (TALEN)
  • Others

 

On the basis of application, Global Market is segmented as:

  • Cell Line Editing
  • Targeted gene mutation
  • Animal Genome Editing
  • Plant Genome Editing

 

On the basis of product type, Global Market is segmented as:

  • Consumables
  • Instruments and Software

 

On the basis of end-user, Global Market is segmented as:

  • Pharmaceutical companies
  • Biotechnology Companies
  • Academics
  • Clinical Research Organizations

 

Biotechnology and pharmaceutical sectors dominate gene editing market due to its applications in drug discovery and therapeutics. Rise in usage of CRISPR and ZFN, companies are investing in innovative research for development of novel gene editing techniques. Many players are adopting various strategies which include collaborations for R&D outsourcing, mergers and acquisitions, strategic or manufacturing activities are driving the growth of gene editing market. For instance, in 2014, Thermo Fisher acquired Life technologies, to create unbeatable leadership in life sciences, research, speciality diagnostics and applied markets.In 2014, Sigma-Aldrich Corporation (U.S.) entered into an agreement with Broad Institute of MIT and Harvard (U.S.) to use CRISPR technology. High growth potential in emerging regions provides lucrative opportunities to industry players.

 

On the basis of Geographical regions, the gene editing market categorized into five regions:, Europe, North America, Latin America, Asia Pacific, and Middle East & Africa. The gene editing market is dominated by North America due to the strong growth trend in the pharmaceuticals and biotechnology industries. Emerging economies of Asia Pacific and Latin America are expected to show significant growth in the gene editing market due to an increase in the number of laboratories in these regions and development of existing ones for automation of various instrumentation systems, the expansion of leading gene editing companies and increased R&D spending.

 

Some of the players in Global market are Cellectis S.A. (France), Applied Stemcell, Inc. (U.S.),  Genscript (U.S.), Merck KGaA (Germany), Horizon Discovery Group plc,(U.K.), Origene Technologies, Inc. (U.S.), System Biosciences, Inc. (U.S.), Sangamo Therapeutics, Inc.(U.S.), Thermo Fisher Scientific (U.S), and Transposagen Biopharmaceuticals, Inc.(U.S.)

 

  • In July 2017, Cellectiswas granted the European Patent for the invention of the genetically engineering T-cells by adopting RNA-guided endonucleases, such as CRISPR associated protein 9 (Cas9) or Centromere and Promoter Factor 1(Cpf1 )

 

  • In July 2017 Sangamo Therapeutics, Inc. received the U.S.FDA Fast Track designation for in vivo gene editing product candidates SB-318 and SB-913 to treat Mucopolysaccharidosis Type I (MPS I) and MPS II

 

  • In November 2016, OriGene Technologies entered strategic agreement with EdiGene (Beijing, China) for the development of gene-wide knockout cells from laboratory cell lines which are commonly used

 

Global Gene Editing Market Report Outline:

 

  • The report provides granular level information about the market size, regional market share and forecast from 2017-2024
  • The report covers in-detail insights about the competitor’s overview, key findings and their key strategies
  • The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
  • The report tracks recent innovations, key developments and startup’s details that are working in the industry
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario


Location

GEOGRAPHY

PBI Location Map

Global Gene Editing Market Table of Content

 

1. Executive summary

2. Global Gene Editing Market Introduction
2.1. Global Gene Editing Market – Taxonomy
2.2. Global Gene Editing Market –Definitions
2.2.1. Product
2.2.2. Technology
2.2.3. Application
2.2.4. End-User

3. Global Gene Editing Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Gene Editing Market Dynamics – Factors Impact Analysis
3.6. Global Gene Editing Market – Regulations
3.6.1. U.S
3.6.2. Europe
3.6.3. Japan
3.6.4. China
3.7. Global Gene Editing Market – Product Innovations

4. Global Gene Editing Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024
4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis

5. Global Gene Editing Market , By Product, 2013 – 2017 and Forecast, 2018 – 2024
5.1. Instruments and Software
5.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.1.3. Market Opportunity Analysis
5.2. Consumables
5.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.2.3. Market Opportunity Analysis

6. Global Gene Editing Market Forecast, By Technology, 2013 – 2017 and Forecast, 2018 – 2024
6.1. Zinc Finger Nuclease (ZFN)
6.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
6.1.3. Market Opportunity Analysis
6.2. Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)
6.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
6.2.3. Market Opportunity Analysis
6.3. Transcription Activator-Like Effector Nuclease (TALEN)
6.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
6.3.3. Market Opportunity Analysis
6.4. Others
6.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
6.4.3. Market Opportunity Analysis

7. Global Gene Editing Market Forecast, By Application, 2013 – 2017 and Forecast, 2018 – 2024
7.1. Cell Line Editing
7.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.1.3. Market Opportunity Analysis
7.2. Targeted gene mutation
7.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.2.3. Market Opportunity Analysis
7.3. Animal Genome Editing
7.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.3.3. Market Opportunity Analysis
7.4. Plant Genome Editing
7.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.4.3. Market Opportunity Analysis

8. Global Gene Editing Market Forecast, By End-User, 2013 – 2017 and Forecast, 2018 – 2024
8.1. Pharmaceutical companies
8.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.1.3. Market Opportunity Analysis
8.2. Biotechnology Companies
8.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.2.3. Market Opportunity Analysis
8.3. Academics
8.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.3.3. Market Opportunity Analysis
8.4. Clinical Research Organizations
8.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.4.3. Market Opportunity Analysis

9. Global Gene Editing Market Forecast, By Region, 2013 – 2017 and Forecast, 2018 – 2024
9.1. North America
9.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
9.1.3. Market Opportunity Analysis
9.2. Europe
9.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
9.2.3. Market Opportunity Analysis
9.3. Asia-Pacific
9.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
9.3.3. Market Opportunity Analysis
9.4. Latin America
9.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
9.4.3. Market Opportunity Analysis
9.5. Middle East and Africa
9.5.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
9.5.3. Market Opportunity Analysis
9.6. Global Gene Editing Market – Opportunity Analysis Index, By Product, Technology, Application, End-User, and Region, 2018 – 2024

10. North America Gene Editing Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024
10.1. Product Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Instuments and Software
10.1.2. Consumables
10.2. Technology Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.2.1. Zinc Finger Nuclease (ZFN)
10.2.2. Clustered regularly interspaced short palindromic repeats (CRISPR)
10.2.3. Transcription activator-like effector nuclease (TALEN)
10.2.4. Others
10.3. Application Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.3.1. Cell Line Editing
10.3.2. Targeted gene mutation
10.3.3. Animal Genome Editing
10.3.4. Plant Genome Editing
10.4. End-User Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.4.1. Pharmaceutical Companies
10.4.2. Biotechnology Companies
10.4.3. Academics
10.4.4. Clinical Research Organizations
10.5. Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.5.1. U.S.
10.5.2. Canada
10.6. North America Gene Editing Market – Opportunity Analysis Index, By Product Analysis, By Technology, By Application, By End-User, and Country, 2018 – 2024
10.7. North America Gene Editing Market Dynamics – Trends

11. Europe Gene Editing Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024
11.1. Product Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Instuments and Software
11.1.2. Consumables
11.2. Technology Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.2.1. Zinc Finger Nuclease (ZFN)
11.2.2. Clustered regularly interspaced short palindromic repeats (CRISPR)
11.2.3. Transcription activator-like effector nuclease (TALEN)
11.2.4. Others
11.3. Application Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.3.1. Cell Line Editing
11.3.2. Targeted gene mutation
11.3.3. Animal Genome Editing
11.3.4. Plant Genome Editing
11.4. End-User Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.4.1. Pharmaceutical Companies
11.4.2. Biotechnology Companies
11.4.3. Academics
11.4.4. Clinical Research Organizations
11.5. Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.5.1. Germany
11.5.2. UK
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Russia
11.5.7. Poland
11.5.8. Rest of Europe
11.6. Europe Gene Editing Market – Opportunity Analysis Index, By Product Analysis, By Technology, By Application, By End-User and Country, 2018 – 2024
11.7. Europe Gene Editing Market Dynamics – Trends

12. Asia-Pacific Gene Editing Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024
12.1. Product Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Instuments and Software
12.1.2. Consumables
12.2. Technology Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.2.1. Zinc Finger Nuclease (ZFN)
12.2.2. Clustered regularly interspaced short palindromic repeats (CRISPR)
12.2.3. Transcription activator-like effector nuclease (TALEN)
12.2.4. Others
12.3. Application Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.3.1. Cell Line Editing
12.3.2. Targeted gene mutation
12.3.3. Animal Genome Editing
12.3.4. Plant Genome Editing
12.4. End-User Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.4.1. Pharmaceutical Companies
12.4.2. Biotechnology Companies
12.4.3. Academics
12.4.4. Clinical Research Organizations
12.5. Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.5.1. Japan
12.5.2. China
12.5.3. India
12.5.4. ASEAN
12.5.5. Australia & New Zealand
12.5.6. Rest of Asia-Pacific
12.6. Asia-Pacific Gene Editing Market – Opportunity Analysis Index, By Product Analysis, By Technology, By Application, By End-User and Country, 2018 – 2024
12.7. Europe Gene Editing Market Dynamics – Trends

13. Latin America Gene Editing Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024
13.1. Product Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1. Instuments and Software
13.1.2. Consumables
13.2. Technology Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.2.1. Zinc Finger Nuclease (ZFN)
13.2.2. Clustered regularly interspaced short palindromic repeats (CRISPR)
13.2.3. Transcription activator-like effector nuclease (TALEN)
13.2.4. Others
13.3. Application Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.3.1. Cell Line Editing
13.3.2. Targeted gene mutation
13.3.3. Animal Genome Editing
13.3.4. Plant Genome Editing
13.4. End-User Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.4.1. Pharmaceutical Companies
13.4.2. Biotechnology Companies
13.4.3. Academics
13.4.4. Clinical Research Organizations
13.5. Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Argentina
13.5.4. Venezuela
13.5.5. Rest of Latin America
13.6. Latin America Gene Editing Market – Opportunity Analysis Index, By Product Analysis, By Technology, By Application, By End-User and Country, 2018 – 2024
13.7. Latin America Gene Editing Market Dynamics – Trends

14. Middle East and Africa Gene Editing Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024
14.1. Product Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
14.1.1. Instuments and Software
14.1.2. Consumables
14.2. Technology Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.2.1. Zinc Finger Nuclease (ZFN)
14.2.2. Clustered regularly interspaced short palindromic repeats (CRISPR)
14.2.3. Transcription activator-like effector nuclease (TALEN)
14.2.4. Others
14.3. Application Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.3.1. Cell Line Editing
14.3.2. Targeted gene mutation
14.3.3. Animal Genome Editing
14.3.4. Plant Genome Editing
14.4. End-User Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.4.1. Pharmaceutical Companies
14.4.2. Biotechnology Companies
14.4.3. Academics
14.4.4. Clinical Research Organizations
14.5. Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
14.5.1. Gulf Cooperation Council (GCC) Countries
14.5.2. Israel
14.5.3. South Africa
14.5.4. Rest of MEA
14.6. MEA Gene Editing Market – Opportunity Analysis Index, By Product Analysis, By Technology, By Application, By End-User and Country, 2018 – 2024
14.7. MEA Gene Editing Market Dynamics – Trends

15. Competition Landscape
15.1. Strategic Dashboard of Top Market Players
15.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
15.2.1. Cellectis S.A. (France)
15.2.2. Applied Stemcell, Inc. (U.S.)
15.2.3. Genscript (U.S.)
15.2.4. Merck KGaA (Germany)
15.2.5. Horizon Discovery Group plc(U.K.
15.2.6. Origene Technologies, Inc. (U.S.)
15.2.7. System Biosciences, Inc. (U.S.)
15.2.8. Sangamo Therapeutics, Inc.(U.S.)
15.2.9. Thermo Fisher Scientific (U.S)
15.2.10. Transposagen Biopharmaceuticals, Inc.(U.S.)

16. Research Methodology

17. Key Assumptions and Acronyms

A complementary 2hrs free facility through which report buyers can interact with our pool of experienced analysts for any report related queries, clarifications or additional data requirements

 

 

ASIA PACIFIC OFFICE

Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX